ACTRN12606000078550已完成1 期
A phase I (dose escalation) study of oral albendazole in patients with cancer refractory to conventional treatments to determine optimal dosing in cancer patients
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 ot stated（—）
- 性别
- All
入选标准
- •1. Histologically or cytologically proven advanced or metastatic cancer2. Patients must have measurable (by imaging studies such as CT but not bone scan) or evaluable disease 3. Refractory to conventional treatments 4. A maximum of two previous systemic myelosuppressive chemotherapy regimens.5. Eastern Co-operative Oncology Group score (ECOG) 0-3 performance status.6. Patients with previously treated CNS (central nervous system) metastases are eligible, provided there is no clinical or radiological evidence of on-going CNS disease progression.7. Patients must have recovered from the reversible side effects of prior therapy.8. At least 3 weeks since prior chemotherapy (at least 6 weeks for agents known to be toxic to stem cells such as nitrosoureas, melphalan, or mitomycin).9. At least 2 weeks since any prior radiotherapy. No more than 25% of bone marrow may have been irradiated in the past.10. Patients of all races and ethnic backgrounds are eligible.11. Adequate Haematological function12. Absolute neutrophils > 1,500/mm3, platelets > 100,000/mm3, 13. bilirubin < 2x upper limit normal 14. Alanine amino transferase/aspartate amino transferase < 10 x upper limit of normal, 15. Calculated creatinine clearance > 60 mls/min.
排除标准
- •1. Patients with unresolved ongoing infection requiring treatment.2. Decompensated liver disease with non malignant ascites or coagulopathy or encephalopathy3. Severe comorbidity at the discretion of the investigators4. Pregnancy or breast feeding mothers.
研究者
相似试验
进行中（未招募）
1 期
Phase I/II dose-escalation study of oral administration of the Pan-Histone Deacetylase (HDAC) Inhibitor S 78454 in Hodgkin’s Disease, non-Hodgkin Lymphoma and Chronic Lymphocytic LeukaemiaHodgkin's disease (HD) , non-Hodgkin lymphoma (NHL) and chronic lymphocytic Leukaemia (CLL)MedDRA version: 12.0Level: LLTClassification code 10020206Term: Hodgkin's diseaseMedDRA version: 12.0Level: LLTClassification code 10029547Term: Non-Hodgkin's lymphomaMedDRA version: 12.0Level: LLTClassification code 10008993Term: Chronic lymphoid leukaemiaEUCTR2009-013691-47-FRInstitut de Recherches Internationales Servier
进行中（未招募）
1 期
Phase I/II dose-escalation study of S 78454 in LymphomaHodgkin's disease (HD) , non-Hodgkin lymphoma (NHL) and chronic lymphocytic Leukaemia (CLL)MedDRA version: 18.0 Level: PT Classification code 10029547 Term: Non-Hodgkin's lymphoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0 Level: PT Classification code 10020206 Term: Hodgkin's disease System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0 Level: LLT Classification code 10008993 Term: Chronic lymphoid leukaemia System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-013691-47-GBPharmacyclics LLC135
进行中（未招募）
1 期
Phase I/II dose-escalation study of S 78454 in LymphomaEUCTR2009-013691-47-HUPharmacyclics LLC156
进行中（未招募）
1 期
Phase I/II dose-escalation study of S 78454 in LymphomaEUCTR2009-013691-47-BEPharmacyclics. LLC156
终止
1 期
Phase I dose-escalation study of oral administration of S055746 in patients with Acute Myeloid Leukaemia or Myelodysplastic SyndromeCancerISRCTN73586707Institut de Recherches Internationales Servier (France)80